Abstract
The recent success of kinase inhibitors targeting the B cell receptor downstream molecules BTK (ibrutinib and PI3K (idelalisib), their characteristic clinical activity with chronic lymphocytic leukemia (CLL) cell redistribution from tissues into the blood, and their unique mechanism, interception of critical CLL - microenvironment interactions and signaling pathways, emphasize that the CLL microenvironment is a critical player in CLL pathogenesis and key for development of new targeted treatment approaches.
| Original language | English (US) |
|---|---|
| Title of host publication | Hodgkin and Non-Hodgkin Lymphomas Seen through Their Microenvironment |
| Subtitle of host publication | Impact on Diagnosis, Prognosis and Innovative Therapy |
| Publisher | Future Medicine Ltd. |
| Pages | 56-71 |
| Number of pages | 16 |
| Volume | 2 |
| ISBN (Electronic) | 9781780845821 |
| ISBN (Print) | 9781780845845 |
| DOIs | |
| State | Published - Jun 1 2015 |
ASJC Scopus subject areas
- General Medicine